Seres Therapeutics, Inc. and Nestlé Health Science announced that VOWST (fecal microbiota spores, live-brpk) is now commercially available for patients. VOWST,formerly called SER-109, is the first and only U.S. Food and Drug Administration (FDA)-approved orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). VOWST is not indicated for the treatment of CDI.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.614 USD | -28.03% | -38.60% | -56.14% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.14% | 92.99M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™